Evommune reports Q2 2026 results, sets EVO756 AD data for September
The company also discontinued EVO756 development in chronic spontaneous urticaria and pointed to cash lasting through 2028.
Evommune, Inc. reported financial results and business updates for the quarter ended June 30, 2026, on August 6, 2026.
The company said it expects to report top-line data in September 2026 from a fully-enrolled Phase 2b dose-ranging trial testing EVO756 in 120 patients with moderate-to-severe atopic dermatitis, with the primary endpoint being percent change in Eczema Area and Severity Index score from baseline at Week 12.1 Secondary measures in that study include the proportion of patients reaching 50% and 75% reductions in EASI, along with results on the Pruritus-NRS scale used to gauge itch severity.1
Separately, Evommune started a global, randomized, double-blind, placebo-controlled Phase 2b dose-ranging trial of EVO756 for migraine prevention in July 2026, enrolling about 330 adults with refractory migraine who have at least six migraine days a month across two active-dose arms and placebo, testing daily doses up to 100 mg over 12 weeks, with top-line data expected in 2027.1 The primary endpoint is the mean change from baseline in monthly migraine days.1
In June 2026, Evommune reported that a Phase 2b trial of EVO756 in adults with moderate-to-severe chronic spontaneous urticaria failed to meet its primary endpoint of change in Urticaria Activity Score over seven days at 12 weeks at any dose tested.1 Following that result, the company discontinued EVO756 development in CSU and is now focusing on atopic dermatitis and migraine.1
On the second program, full results from a positive Phase 2a trial of EVO301 in adult atopic dermatitis patients will be presented at an upcoming medical conference, including secondary endpoint and biomarker data.1 A planned Phase 2b trial of EVO301 in atopic dermatitis, testing at least three subcutaneous dosing regimens over 16 weeks, is expected to begin in mid-2027 following manufacturing scale-up and toxicology work.1
Financially, Evommune held $288.0 million in cash, cash equivalents and investments as of June 30, 2026, up from $216.7 million at the end of 2025.1 The company said this gives it cash through 2028 to fund multiple pipeline data readouts.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.